Philadelphia Chromosome Positive Recruiting Phase 2 Trials for Blinatumomab (DB09052)

Also known as: Philadelphia chromosome positive

IndicationStatusPhase
DBCOND0046287 (Philadelphia Chromosome Positive)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02143414Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic LeukemiaTreatment
NCT03263572Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic LeukemiaTreatment
NCT02458014Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual DiseaseTreatment
NCT02997761Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic LeukemiaTreatment